<DOC>
	<DOCNO>NCT01672450</DOCNO>
	<brief_summary>This single center , open phase I dose escalation study . This study assess high tolerable intratumoral dose ipilimumab ( Yervoy ) combination IL-2 ( Proleukin ) patient unresectable stage III-IV melanoma accessible cutaneous , subcutaneous , and/or nodal lesion . The objective primarily assess safety drug combination , secondarily obtain preliminary data clinical efficacy combination .</brief_summary>
	<brief_title>A Study Intratumoral Injection Interleukin-2 Ipilimumab Patients With Unresectable Stages III-IV Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histological diagnosis melanoma , unresectable stage IIIIV accessible cutaneous , subcutaneous , and/or nodal lesion , accord AJCC Staging Manual , 7th Edition , 2011 . Note : Patients consider resectable disease decline resection eligible . At least one lesion &gt; 0.5 cm &lt; 2 cm ECOG performance status 0 , 1 2 Negative pregnancy test woman childbearing potential within 7 day enrollment study . WBC &gt; 2,000/mm3 ; ANC &gt; 1,000/mm3 ; platelet &gt; 100,000/mm3 ; hemoglobin &gt; 9 gm/dL ( may transfuse ) Serum bilirubin level &lt; 1.5 mg/dL except patient Gilbert 's syndrome . Serum aspartate transaminase ( AST ) serum alanine transaminase ( ALT ) &lt; 2.5 X upper limit normal , alkaline phosphatase &lt; 2.5 X upper limit normal . Serum creatinine level &lt; 1.5 mg/dL Women childbearing potential advise avoid become pregnant men advise father child receive treatment ipilimumab interleukin2 . Patients agree use appropriate method birth control study . Examples adequate form birth control woman include oral implanted contraceptive , intrauterine device ( IUD ) , diaphragm spermicide , cervical cap , abstinence , use condom sexual partner sterile sexual partner also base judgment investigator . Age &gt; 18 year gender race . Able provide inform consent sign approve consent form conform federal institutional guideline . Concurrent therapy nonprotocol anticancer therapy Prior local therapy within 2 week prior systemic therapy within 4 week start protocol treatment History malignancy require active treatment Preexisting autoimmunity : History inflammatory bowel disease ; history symptomatic autoimmune disease ( e.g. , rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , systemic lupus erythematosus , autoimmune vasculitis [ e.g. , Wegener 's Granulomatosis ] ) ; motor neuropathy consider autoimmune origin ( e.g. , GuillainBarre Syndrome ) . History vitiligo allow . Chronic use immunosuppressant systemic corticosteroid . Note : Chronic use define require corticosteroid great one month prior enrollment study . Corticosteroid use le 1 month prior enrollment allow , use must stop prior start study treatment . Clinically significant cardiovascular disease ( e.g. , uncontrolled hypertension [ BP &gt; 150/100 ] , myocardial infarction stroke within 6 month , unstable angina ) , New York Heart Association ( NYHA ) Grade II great congestive heart failure , serious cardiac arrhythmia require medication Currently active systemic infection Known history HIV infection chronic hepatitis B C. The presence medical psychiatric disorder , opinion treat physician , would contraindicate use drug protocol place subject undue risk treatment complication Pregnancy breast feed A history severe hypersensitivity reaction ipilimumab interleukin2 Any reason , opinion investigator , patient participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Histologically cytologically proven melanoma ; Stages III-IV ; accessible cutaneous , subcutaneous , and/or nodal lesion ; ECOG performance status 0 2</keyword>
</DOC>